Drug Trial Radar · NCT05710198
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
873
Actual
Start
Dec 11, 2023
Primary completion
Jul 1, 2029
Study completion Jul 1, 2029
Sponsor
- Lead sponsor
- Omikron Italia S.r.l.Industry
- Sponsor type
- Industry
- Collaborators
- OPIS Spain
- First posted
- Feb 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%
Conditions
- Glaucoma, Open-Angle
Interventions
Citicoline eye drops 2%Drug
Eye drops containing Citicoline 2%
PlaceboDrug
Eye drops containing placebo matching product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression of visual field damageTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Presidio Ospedale San Paolo
Milan, MI, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.